Risk criteria | All extrameningeal SFT | Extrameningeal, extrapleural SFT only | ||||||||
Demicco et al, 2017* | Salas et al, 2017¶ | Georgiesh et al, 2020Δ | Pasquali et al, 2016 | |||||||
Points | Points | Points | Points | |||||||
Mitoses (per 10 HPF) | 0 | 0 | ≤4 | ≤4 | 0 | <4 | 0 | ≤4 | 0 | |
1-3 | 1 | >4 | >4 | 1 | ≥4 | 2 | >4 | 3 | ||
≥4 | 2 | |||||||||
Age (years) | <55 | 0 | <60 | <60 | ≥60 | 0 | ||||
≥55 | 1 | ≥60 | ≥60 | <60 | 1 | |||||
Sex | Female | 0 | ||||||||
Male | 1 | |||||||||
Site | Other | Other | 0 | |||||||
Limb | Viscera | 1 | ||||||||
Size | 0-4.9 cm | 0 | ||||||||
5-9.9 cm | 1 | |||||||||
10-14.9 cm | 2 | |||||||||
≥15 cm | 3 | |||||||||
Necrosis | <10% | 0 | Absent | 0 | ||||||
≥10% | 1 | <50% | 1 | |||||||
≥50% | 2 | |||||||||
Cellularity | Low | 0 | ||||||||
Moderate-high | 2 | |||||||||
Nuclear pleomorphism | Low | 0 | ||||||||
Moderate-high | 2 | |||||||||
Radiation therapy | Yes | 0 | ||||||||
No | 1 | |||||||||
Risk for metastases | Points | Risk for metastases | Risk for adverse or poor OS | Risk for LR | Points | Risk for recurrence | Points | Risk for recurrence◊ | Points | |
Risk sum stratification | Low | 0-3 | Very low | Low | Very low | 0 | Low | 0 | Very low | 0 |
Intermediate | 4-5 | Low | Intermediate | Low | 1 | Intermediate | 1-2 | Low | 2 | |
High | 6-7 | Intermediate | High | Intermediate | 2 | High | 3-5 | Intermediate | 3-5 | |
High | High | 3 | High | >5 |
Do you want to add Medilib to your home screen?